Skip to main content
NCBI home page
Thorax logoLink to Thorax
. 1998 Aug;53(8):656–661. doi: 10.1136/thx.53.8.656

Fluticasone propionate 750 µg/day versus beclomethasone dipropionate 1500 µg/day: comparison of efficacy and adrenal function in paediatric asthma

D Fitzgerald 1, P Van Asperen 1, C Mellis 1, M Honner 1, L Smith 1, G Ambler 1
PMCID: PMC1745293  PMID: 9828851

Abstract

BACKGROUND—Previous studies have suggested a 2:1 efficacy advantage of fluticasone propionate (FP) over beclomethasone dipropionate (BDP) in adults on high dose inhaled steroids and children on low dose inhaled steroids. The lower doses of FP required to provide equivalent efficacy to BDP also appear to have fewer systemic effects as measured by adrenal function.
METHODS—The efficacy and safety of FP 750 µg/day and BDP 1500 µg/day were compared in 30 children with persistent asthma (requiring 1000-2000 µg/day of inhaled corticosteroids) in a 12 week randomised double blind crossover study. Medication was delivered by a spacer device in two divided doses. Primary efficacy variables were peak expiratory flows (PEF). Adrenal function was assessed by 24 hour urinary free cortisol levels at eight and 12 weeks and ACTH and low dose synacthen tests (LDST) at 12 weeks. The results were adjusted for sequence and period differences.
RESULTS—There was no difference in the primary efficacy variables over the two 12 week treatment periods (difference in adjusted means for morning PEF 1.3 l/min (95% CI -6.1 to 8.8), p = 0.112) and symptom scores (cough, tachypnoea, wheeze, shortness of breath; difference in adjusted means of night time scores: -0.06 (95% CI -0.14 to 0.03); p = 0.136). Similar degrees of mild adrenal dysfunction were found during BDP and FP treatment phases. Identical height gain velocities were shown during the corresponding periods.
CONCLUSIONS—FP 750 µg/day is as effective as BDP 1500 µg/day in children with persistent asthma. At these very high doses we were unable to demonstrate a safety advantage of FP over BDP as assessed by adrenal function. However, measures of adrenal function may have been influenced by concurrent and previous systemic steroid usage, and possibly by effects of disease activity.



Full Text

The Full Text of this article is available as a PDF (122.8 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Agertoft L., Pedersen S. Effects of long-term treatment with an inhaled corticosteroid on growth and pulmonary function in asthmatic children. Respir Med. 1994 May;88(5):373–381. doi: 10.1016/0954-6111(94)90044-2. [DOI] [PubMed] [Google Scholar]
  2. Barnes N. C., Marone G., Di Maria G. U., Visser S., Utama I., Payne S. L. A comparison of fluticasone propionate, 1 mg daily, with beclomethasone dipropionate, 2 mg daily, in the treatment of severe asthma. International Study Group. Eur Respir J. 1993 Jun;6(6):877–885. [PubMed] [Google Scholar]
  3. Barnes P. J., Pedersen S. Efficacy and safety of inhaled corticosteroids in asthma. Report of a workshop held in Eze, France, October 1992. Am Rev Respir Dis. 1993 Oct;148(4 Pt 2):S1–26. doi: 10.1164/ajrccm/148.4_Pt_2.S1. [DOI] [PubMed] [Google Scholar]
  4. Broide J., Soferman R., Kivity S., Golander A., Dickstein G., Spirer Z., Weisman Y. Low-dose adrenocorticotropin test reveals impaired adrenal function in patients taking inhaled corticosteroids. J Clin Endocrinol Metab. 1995 Apr;80(4):1243–1246. doi: 10.1210/jcem.80.4.7714095. [DOI] [PubMed] [Google Scholar]
  5. Dickstein G., Shechner C., Nicholson W. E., Rosner I., Shen-Orr Z., Adawi F., Lahav M. Adrenocorticotropin stimulation test: effects of basal cortisol level, time of day, and suggested new sensitive low dose test. J Clin Endocrinol Metab. 1991 Apr;72(4):773–778. doi: 10.1210/jcem-72-4-773. [DOI] [PubMed] [Google Scholar]
  6. Doull I. J., Donovan S. J., Wood P. J., Holgate S. T. Bloodspot cortisol in mild asthma: the effect of inhaled corticosteroids. Arch Dis Child. 1995 Apr;72(4):321–324. doi: 10.1136/adc.72.4.321. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Enright P. L., Sherrill D. L., Lebowitz M. D. Ambulatory monitoring of peak expiratory flow. Reproducibility and quality control. Chest. 1995 Mar;107(3):657–661. doi: 10.1378/chest.107.3.657. [DOI] [PubMed] [Google Scholar]
  8. Fabbri L., Burge P. S., Croonenborgh L., Warlies F., Weeke B., Ciaccia A., Parker C. Comparison of fluticasone propionate with beclomethasone dipropionate in moderate to severe asthma treated for one year. International Study Group. Thorax. 1993 Aug;48(8):817–823. doi: 10.1136/thx.48.8.817. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Goldstein D. E., König P. Effect of inhaled beclomethasone dipropionate on hypothalamic-pituitary-adrenal axis function in children with asthma. Pediatrics. 1983 Jul;72(1):60–64. [PubMed] [Google Scholar]
  10. Gustafsson P., Tsanakas J., Gold M., Primhak R., Radford M., Gillies E. Comparison of the efficacy and safety of inhaled fluticasone propionate 200 micrograms/day with inhaled beclomethasone dipropionate 400 micrograms/day in mild and moderate asthma. Arch Dis Child. 1993 Aug;69(2):206–211. doi: 10.1136/adc.69.2.206. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Hamill P. V., Drizd T. A., Johnson C. L., Reed R. B., Roche A. F., Moore W. M. Physical growth: National Center for Health Statistics percentiles. Am J Clin Nutr. 1979 Mar;32(3):607–629. doi: 10.1093/ajcn/32.3.607. [DOI] [PubMed] [Google Scholar]
  12. Harding S. M. The human pharmacology of fluticasone propionate. Respir Med. 1990 Nov;84 (Suppl A):25–29. doi: 10.1016/s0954-6111(08)80004-2. [DOI] [PubMed] [Google Scholar]
  13. Isles A. F., Robertson C. F. Treatment of asthma in children and adolescents: the need for a different approach. Med J Aust. 1993 Jun 7;158(11):761–763. doi: 10.5694/j.1326-5377.1993.tb121958.x. [DOI] [PubMed] [Google Scholar]
  14. Lipworth B. J. New perspectives on inhaled drug delivery and systemic bioactivity. Thorax. 1995 Feb;50(2):105–110. doi: 10.1136/thx.50.2.105. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. MacKenzie C. A., Weinberg E. G., Tabachnik E., Taylor M., Havnen J., Crescenzi K. A placebo controlled trial of fluticasone propionate in asthmatic children. Eur J Pediatr. 1993 Oct;152(10):856–860. doi: 10.1007/BF02073387. [DOI] [PubMed] [Google Scholar]
  16. Merkus P. J., van Essen-Zandvliet E. E., Duiverman E. J., van Houwelingen H. C., Kerrebijn K. F., Quanjer P. H. Long-term effect of inhaled corticosteroids on growth rate in adolescents with asthma. Pediatrics. 1993 Jun;91(6):1121–1126. [PubMed] [Google Scholar]
  17. Ninan T. K., Reid I. W., Carter P. E., Smail P. J., Russell G. Effects of high doses of inhaled corticosteroids on adrenal function in children with severe persistent asthma. Thorax. 1993 Jun;48(6):599–602. doi: 10.1136/thx.48.6.599. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Reiser J., Warner J. O. The value of participating in an asthma trial. Lancet. 1985 Jan 26;1(8422):206–207. doi: 10.1016/s0140-6736(85)92037-9. [DOI] [PubMed] [Google Scholar]
  19. Russell G. Inhaled corticosteroid therapy in children: an assessment of the potential for side effects. Thorax. 1994 Dec;49(12):1185–1188. doi: 10.1136/thx.49.12.1185. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Van Asperen P. P., Mellis C. M., Sly P. D. The role of corticosteroids in the management of childhood asthma. The Thoracic Society of Australia and New Zealand. Med J Aust. 1992 Jan 6;156(1):48–52. [PubMed] [Google Scholar]

Articles from Thorax are provided here courtesy of BMJ Publishing Group

RESOURCES